The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) — Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU)
Switching off the ovaries reduces the risk of breast cancer recurrence by one-fifth in younger women
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) aggregates data from over 700,000 women across 650 randomised controlled trials of early breast cancer treatments, providing definitive evidence on surgery, radiotherapy, chemotherapy, endocrine therapy, and biologic agents.
EBCTCG findings are widely used to inform clinical guidelines and shape treatment decisions, contributing to global reductions in breast cancer mortality.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC